Phase I study of Wilms' tumor gene WT1 peptide pulsed dendritic cell vaccination combined with docetaxel for patients with advanced or recurrent esophageal cancer
Phase 1
- Conditions
- Advanced or recurrent esophageal cancer
- Registration Number
- JPRN-UMIN000006704
- Lead Sponsor
- School of Medicine, Keio University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
1)Tracheo-esophageal fistula 2)Symptomatic brain metastasis 3)Active other primary malignancies 4)Past history of severe allergy 5)Severe comorbidity (infections, interstitial pneumonia, fibroid lung, cardiovascular disease, renal disease, liver disease, uncontrolled diabetes) 6)Pleural effusion or pericardial fluid requiring treatment 7)Pregnancy, nursing women 8)Male hope to impregnate 9)Severe psychiatric disease 10)Active autoimmune disease 11)During treatment with immunosuppressive agents 12)Patients whom doctors judged inadequate to the enrollment of this study by other reasons
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Advertise events
- Secondary Outcome Measures
Name Time Method Response rate Progression free survival Overall survival Immune induction (Delayed type hypersensensitivity DTH for WT1 peptide)